Erin Duggan | Senior Director of Communications | Mass. Eye and Ear
617-573-3756 | Erin_Duggan@meei.harvard.edu
Boston, Mass. — An adhesive gel packed with light-activated chemicals can seal cuts or ulcers on the cornea —the clear surface of the eye — and then encourage the regeneration of corneal tissue, according to a preclinical study published online today in Science Advances. The new technology, named GelCORE (gel for corneal regeneration), could one day reduce the need for surgery to repair injuries to the cornea, including those that would today require corneal transplantation.
“Our hope is that this biomaterial could fill in a major gap in technology available to treat corneal injuries,” said co-corresponding author Reza Dana, MD, Director of the Cornea and Refractive Surgery Service at Massachusetts Eye and Ear and the Claes H. Dohlman Professor of Ophthalmology at Harvard Medical School. “We set out to create a material that is clear, strongly adhesive, and permits the cornea to not only close the defect, but also to regenerate. We wanted this material to allow the cells of the cornea to mesh with the adhesive and to regenerate over time to mimic something as close to the native cornea as possible.”
Corneal injuries are a common cause of visual impairment worldwide, with more than 1.5 million new cases of corneal blindness reported every year. The current standard of care for filling in cuts, thinning areas, or holes in the cornea (corneal defects) includes the use of synthetic glues or surgery to patch the eye with tissue and/or corneal transplants. The synthetic glues currently available are rough, inherently toxic to tissues, difficult to handle, and can lead to significant vision loss due to the material’s opacity and poor integration with corneal tissues. Corneal transplants carry risks of post-transplant complications, including infection or rejection.
With the goal of addressing this unmet clinical need, researchers on the Science Advances report set out to develop an adhesive designed for long-term integration with the cornea.
The team engineered an adhesive biomaterial, GelCORE, made of chemically modified gelatin and photoinitiators, which are activated by a short-time exposure to blue light. Initially, the gel is a clear, viscous material designed to be applied with a dropper or syringe. When exposed to light, the material hardens, taking on the biomechanical features of a native cornea. And, over time, the cornea cells gradually grow into and become one with this material. Thus, GelCORE is similar to the native cornea — highly transparent, able to bond to the native tissue, and capable of supporting cell and tissue regeneration.
Similar adhesive technologies have been designed for lung and other eye defects, but GelCORE is the first to use visible blue light as opposed to ultraviolet light, which carries a level of toxicity that blue light does not.
In the Science Advances report, the researchers describe their assessments of GelCORE in a preclinical model of corneal injury. They applied GelCORE at 20 percent concentration to corneal defects of 3mm, and then applied visible light for 4 minutes. Immediately after the light exposure, they observed firm adhesion of the gel to the corneal defect. One day later, they observed a transparent, smooth eye surface, with a surrounding cornea that was clear and without inflammation. One week after application, the gel could still be observed on the defect site in the cornea and remained transparent. Over time, the tissue showed signs of regeneration, with cells of the new tissue showing similarities between regenerated tissue and native tissue.
The study authors also note that the properties of GelCORE can be finely controlled by varying the concentration and the amount of time exposed to light — offering the possibility of changing the formulation for different types and severities of eye injuries. “We’re now looking to make certain modifications for different applications,” Dr. Dana said. “We envision, if a patient comes in with a big laceration, they might receive formulation A. If they come in with a corneal scar, they might get formulation B.” The authors also hope to begin clinical trials to test the technology in human patients in approximately one year.
In addition to Dr. Dana, co-authors on the Science Advances report include co-corresponding author Nasim Annabi, PhD, co-first author Ehsan Shirzaei Sani, Amir Sheikhi, PhD, and Ali Khademhosseini, PhD, of the University of California at Los Angeles, co-first author Ahmad Kheirkhah, MD, William Foulsham, MD, and Zhongmou Sun of Massachusetts Eye and Ear/Harvard Medical School, and Devyesh Rana of Northeastern University. The study was supported by National Institutes of Health grants R01EB023052 and R01HL140618, American Heart Association Grant 165SDG31280010, Department of Defense grant W81XWH-18-1-0654, Research to Prevent Blindness Stein Innovation Award and the Canadian Institutes of Health Research. Drs. Dana and Annabi are inventors on a patent application related to this work filed by Massachusetts Eye and Ear and Brigham and Women’s Hospital.
About Massachusetts Eye and Ear
Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of Partners HealthCare, Mass. Eye and Ear specializes in ophthalmology (eye care) and otolaryngology–head and neck surgery (ear, nose and throat care). Mass. Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass. Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 2018-2019 "Best Hospitals Survey," U.S. News & World Report ranked Mass. Eye and Ear #4 in the nation for eye care and #6 for ear, nose and throat care. For more information about life-changing care and research at Mass. Eye and Ear, please visit our blog, Focus, and follow us on Instagram, Twitter and Facebook.
About Harvard Medical School Department of Ophthalmology
The Harvard Medical School Department of Ophthalmology is one of the leading and largest academic departments of ophthalmology in the nation. More than 400 full-time faculty and trainees work at nine Harvard Ophthalmology affiliate institutions, including Massachusetts Eye and Ear, Schepens Eye Research Institute of Massachusetts Eye and Ear, Massachusetts General Hospital, Brigham and Women’s Hospital, Boston Children’s Hospital, Beth Israel Deaconess Medical Center, Joslin Diabetes Center/Beetham Eye Institute, Veterans Affairs Boston Healthcare System, VA Maine Healthcare System, and Cambridge Health Alliance. Formally established in 1871, the department has been built upon a strong and rich foundation in medical education, research, and clinical care. Through the years, faculty and alumni have profoundly influenced ophthalmic science, medicine, and literature—helping to transform the field of ophthalmology from a branch of surgery into an independent medical specialty at the forefront of science.